---
title: Phase II Study of Inotuzumab Ozogamicin for Measurable Residual Disease in
  Acute Lymphoblastic Leukemia in Remission
date: '2023-10-25'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37879077/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20231026180809&v=2.17.9.post6+86293ac
source: Blood
description: The detection of measurable residual disease (MRD) is the strongest predictor
  of relapse in acute lymphoblastic leukemia (ALL). Using inotuzumab ozogamicin in
  the setting of MRD may improve outcomes. Patients with ALL in first complete remission
  (CR1) or beyond (CR2+) with MRD ≥1x10-4 were enrolled in this phase II trial. Inotuzumab
  was administered at 0.6 mg/m2 on Day 1 and 0.3 mg/m2 on Day 8 of cycle 1, then at
  0.3 mg/m2 on Days 1 and 8 of cycles 2-6. Twenty-six consecutive patients with ...
disable_comments: true
---
The detection of measurable residual disease (MRD) is the strongest predictor of relapse in acute lymphoblastic leukemia (ALL). Using inotuzumab ozogamicin in the setting of MRD may improve outcomes. Patients with ALL in first complete remission (CR1) or beyond (CR2+) with MRD ≥1x10-4 were enrolled in this phase II trial. Inotuzumab was administered at 0.6 mg/m2 on Day 1 and 0.3 mg/m2 on Day 8 of cycle 1, then at 0.3 mg/m2 on Days 1 and 8 of cycles 2-6. Twenty-six consecutive patients with ...